论文部分内容阅读
目的观察盐酸罗格列酮治疗2型糖尿病的临床疗效及其毒副作用。方法39例2型糖尿病患者,每日早餐前口服盐酸罗格列酮片4mg,治疗随访至少4次,疗程12周。观察治疗前后空腹血糖(FBG)、餐后2h血糖(2hPBG)、糖化血红蛋白(HbA1c)、空腹和餐后2h胰岛素以及血尿素氮(BUN)、血肌酐(Cr)、血尿酸(UA)、甘油三酯(TG)、总胆固醇(TC)、高密度脂蛋白-胆固醇(HDL-C)、低密度脂蛋白-胆固醇(LDL-C)等指标的变化情况。结果HbA1c治疗前(8.3±1.7)%,治疗后(7.5±1.4)%;FBG治疗前(8.9±1.9)mmol/L,治疗后(7.8±1.8)mmol/L;2hPBG治疗前(14.0±4.0)mmol/L,治疗后(12.0±4.0)mmol/L;餐后2h胰岛素治疗前(27.0±22.0)mU/L,治疗后(22.0±18.0)mU/L。上述指标治疗后较治疗前均明显下降(P均<0.05)。结论盐酸罗格列酮治疗2型糖尿病可有效降低血糖和HbA1c,疗效好,毒副作用小。
Objective To observe the clinical efficacy and side effects of rosiglitazone hydrochloride in the treatment of type 2 diabetes mellitus. Methods Thirty-nine patients with type 2 diabetes mellitus were treated with oral administration of 4 mg of rosiglitazone hydrochloride daily before breakfast. The patients were followed up for at least 4 times for 12 weeks. Fasting blood glucose (FBG), postprandial 2h blood glucose (2hPBG), HbA1c, fasting and postprandial 2h insulin and BUN, serum creatinine (Cr), serum uric acid Triglyceride (TG), total cholesterol (TC), high-density lipoprotein-cholesterol (HDL-C) and low density lipoprotein-cholesterol (LDL- Results Before treatment with HbA1c (8.3 ± 1.7%) and after treatment (7.5 ± 1.4%), FBG before treatment was (8.9 ± 1.9) mmol / L and after treatment ) mmol / L, after treatment (12.0 ± 4.0) mmol / L; 2 h postprandial insulin treatment (27.0 ± 22.0) mU / L and 22.0 ± 18.0 mU / L after treatment. The above indexes were significantly lower after treatment than before treatment (all P <0.05). Conclusion Rosiglitazone hydrochloride treatment of type 2 diabetes can effectively reduce blood glucose and HbA1c, with good curative effect and little side effects.